Finance

Lists
GNMSF:OTCMKTS
Genmab A/S
367,00 $
0,00%
(0,00) 1D
9 қаз., 10:28:36 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GNMSF...
Mkt. cap
22,76 млрд
Avg. vol.
1,37 мың
Volume
180,00
52-wk high
396,97 $
52-wk low
232,50 $
Beta
0,73
Shares outstanding
62,41 млн
No. of employees
3 мың
Mkt. cap
22,76 млрд
Avg. vol.
1,37 мың
Volume
180,00
52-wk high
396,97 $
52-wk low
232,50 $
Beta
0,73
Shares outstanding
62,41 млн
No. of employees
3 мың
News stories
From web sources and news partners
Profile
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab Co., Ltd. in Suzhou, China. Genmab is listed on the Copenhagen Stock Exchange in Denmark, with American depositary receipts traded on the NASDAQ in the US. Wikipedia
About Genmab A/S
CEOJan G. J. van de Winkel
Employees3,12 мың
Founded1998 ж. 11 мау.
Headquarters-
Sector-
Websitegenmab.com
Previous reportsAll values in DKK
Loading Previous Earnings...
Revenue
Net income
All values in DKK
2023 ж. жел.
2024 ж. нау.
2024 ж. мау.
2024 ж. қыр.
Revenue
4,68 млрд
4,14 млрд
5,40 млрд
5,54 млрд
Cost of goods sold
-
-
-
273,00 млн
Cost of revenue
-
-
-
273,00 млн
Research and development expenses
-
-
-
2,28 млрд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
-
-
865,00 млн
Operating expense
-
-
-
3,15 млрд
Total operating expenses
-
-
-
3,42 млрд
Operating income
-
-
-
2,12 млрд
Other non operating income
-
-
-
-
EBT including unusual items
-
-
-
1,72 млрд
EBT excluding unusual items
-
-
-
1,59 млрд
Income tax expense
-
-
-
453,00 млн
Effective tax rate
-
-
-
26,35%
Other operating expenses
-
-
-
-
Net income
-
-
-
1,27 млрд
Net profit margin
-
-
-
22,85%
Earnings per share
9,67
-
-
19,81
Interest and investment income
-
-
-
162,00 млн
Interest expense
-
-
-
-18,00 млн
Net interest expenses
-
-
-
144,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
2,20 млрд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google қолданбалары